42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Exclusion Criteria

• •Body mass index \>42
• •Red blood cell transfusion within 12 weeks
• •Androgen therapy within the previous 21 days prior to study dosing
• •Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 11 weeks prior to the Screening visit
• •Participants meeting the criteria of ESA resistance within the previous 4 months
• •Individual doses of intravenous iron of greater than 250 mg within the past 21 days
• •Aspartate aminotransferase or alanine aminotransferase \>1.8x upper limit of normal (ULN)
• •Alkaline phosphatase \>2x ULN
• •Total bilirubin \>1.5x ULN
• •Uncontrolled hypertension
• •New York Heart Association Class III or IV congestive heart failure
• •Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to dosing